Health Economics›Head and neck cancer›Recurrent or metastatic disease first-line therapy

Recurrent or metastatic disease first-line therapy

Head and neck cancer · 19 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 4 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	—	11.6 mo	2	R 573 911 PFS proxy	1
Cisplatin and Cetuximab Variant #01	—	R 102 161	28d	—	—	~3	~R 150 580 indirect	—
Carboplatin, Fluorouracil, Pembrolizumab Variant #01	—	R 83 972	21d	—	13.0 mo	35	R 2 881 461 PFS proxy	1
Cisplatin and Fluorouracil (CF) and Pembrolizumab Variant #01	—	R 83 223	21d	—	13.0 mo	35	R 2 876 965 PFS proxy	1
Carboplatin, Fluorouracil, Cetuximab Variant #01	—	R 79 936	21d	—	10.7 mo	6	R 267 021 PFS proxy	3
Cisplatin and Fluorouracil (CF) and Cetuximab Variant #03	—	R 78 877	29d	5.5 mo	10.9 mo	6	R 260 671 PFS proxy	5
Cisplatin and Fluorouracil (CF) and Panitumumab Variant #01	—	R 39 117	21d	—	11.1 mo	6	R 234 699 PFS proxy	1
Celecoxib, Erlotinib, Methotrexate, Nivolumab Variant #01 Partial	—	R 10 695	21d	—	—	2	R 21 389 PFS proxy	1
Carboplatin and Docetaxel (DCb) Variant #06	—	R 5 501	21d	~4.7 mo	~22.3 mo	~6	~R 33 004 PFS proxy · indirect	4
Celecoxib, Erlotinib, Methotrexate Variant #01	—	R 3 565	7d	—	—	2	R 7 130 PFS proxy	1
Cisplatin and Docetaxel (DC) Variant #05	—	R 3 185	21d	—	—	~3	~R 9 556 PFS proxy · indirect	1
Cisplatin and Fluorouracil (CF) Variant #01	—	R 1 783	28d	11.3 mo	9.0 mo	3	R 5 350 PFS proxy	8
Cisplatin and Paclitaxel (TP) Variant #02	—	R 1 315	21d	—	8.1 mo	7	R 9 204 PFS proxy	—
Carboplatin and Fluorouracil Variant #01	—	R 1 070	21d	—	7.4 mo	2	R 2 140 PFS proxy	1
CABO Variant #01 Partial	—	R 1 004	21d	—	—	~2	~R 2 008 indirect	—
Fluorouracil monotherapy Variant #01	—	R 647	28d	—	~10.0 mo	~2	~R 1 294 PFS proxy · indirect	3
Cisplatin monotherapy Variant #01	—	R 588	21d	2.7 mo	6.2 mo	2	R 1 177 PFS proxy	3
Celecoxib and Methotrexate Variant #01	—	R 88	7d	—	7.5 mo	2	R 176 PFS proxy	1
Methotrexate monotherapy Partial	—	—	—	—	6.7 mo	—	—	2

19 of 19 regimens shown